Eli Lilly & Co. has filed a patent infringement lawsuit in the US District Court for the Eastern District of Michigan to safeguard its patent rights over Strattera, generically atomoxetine hydrochloride against the generic drug manufacturer Sun Pharmaceutical Industries, which filed an Abbreviated New Drug Application (ANDA) with the United States Food & Drug Administration seeking regulatory approval to market generic atomoxetine before the expiration of the Orange Book listed US 5,658,590 (the ‘590 patent). The ‘590 patent expires on November 26, 2016, and particularly covers a method of treating attention-deficit/hyperactivity disorder by administrating an effective amount of tomoxetine. Earlier, on August 09, 2007 and August 27, 2007 Eli Lilly filed patent infringement lawsuits for same drug in the US District Court for the District of New Jersey against Actavis Elizabeth LLC and Sandoz Inc.
No comments:
Post a Comment